A Université de Montréal professor and his team believe they have made a breakthrough discovery about a poorly understood illness that affects thousands of Quebecers and has significant ties to long COVID.
In a recently published study, Dr. Alain Moreau identifies a potential new biomarker and therapeutic target for myalgic encephalomyelitis (ME/CFS), once known as chronic fatigue syndrome.
The Gazette's Jesse Feith reports it’s an advancement Moreau believes could revolutionize the diagnosis and treatment of the illness.
